Bimatoprost clinical trials
Also written LUMIGAN® and LATISSE®.
Includes 10 studies of Bimatoprost Ophthalmic Solution.
How each study uses Bimatoprost is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Bimatoprost studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Mar 2001 · LUMIGAN · NDA 021275 (FDA, Drugs@FDA)
- European Union
- 8 Mar 2002 · Lumigan · EMEA/H/C/000391 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
82 studies that test it; most in 2011 (12)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 3 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 5 |
| 2008 | 2 |
| 2009 | 8 |
| 2010 | 9 |
| 2011 | 12 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 8 |
| 2015 | 5 |
| 2016 | 7 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 61 · Other 26
Allergan (43) · AbbVie (4) · ForSight Vision5, Inc. (4) · Innovative Medical (4) · Duke University (2) · University of Miami (2) · Laboratoires Thea (1) · Ahmed Hassan Nouh MD (1)
Often tested with
Tested in the same studies.
Latanoprost (11) · Travoprost (11) · Timolol (10) · Brimonidine (3) · Dorzolamide (2) · Hypromellose Derivatives (2) · Brimonidine Tartrate, Timolol Maleate Drug Combination (1) · Simenepag isopropyl (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Bimatoprost, phase 3 first.
- Nov 2027A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular HypertensionPhase 3 · YS Life Science Co., Ltd.
Studies
Open first, then newest update. How each study uses Bimatoprost is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 87
- A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular HypertensionRecruitingPhase 3YS Life Science Co., Ltd.NCT07661329Written as Bimatoprost ophthalmic solution 0.01% YSBPHow we know
- A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both EyesRecruitingPhase 1Amneal Pharmaceuticals, LLCNCT06267274Written as Bimatoprost Ophthalmic Solution, 0.01%How we know
- Treatment of Hypopigmented Scars With BimatoprostRecruitingPhase 2Medstar Health Research InstituteNCT06122090Written as BimatoprostHow we know
- Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3AbbVieNCT03850782Written as Bimatoprost (SR)How we know
- Long-term Safety and Efficacy Extension Trial of Bimatoprost SRCompletedPhase 3AbbVieNCT03891446Written as Bimatoprost SRHow we know
- Stop Retinal Ganglion Cell Dysfunction StudyTerminatedPhase 3University of MiamiNCT02390284Written as BimatoprostHow we know
- Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3AbbVieNCT02507687Written as Bimatoprost SRHow we know
- Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous PatientsCompletedPhase 3Laboratoires TheaNCT03825380Written as BimatoprostHow we know
- A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3AbbVieNCT04285580Written as Bimatoprost SRHow we know
- Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia AreataCompletedPhase 1/2Ahmed Hassan Nouh MDNCT05600673Written as Bimatoprost 0.03% solutionHow we know
- Effect of Microneedling, Bimatoprost and Excimer in Vitiligo TreatmentCompletedEarly Phase 1Medical University of South CarolinaNCT04738149Written as BimatoprostHow we know
- A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3AllerganNCT02636946Written as Bimatoprost SRHow we know
- Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension GlaucomaStatus unknownPhase 4Salus UniversityNCT04981886Written as Bimatoprost OphthalmicHow we know
- Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3AllerganNCT02250651Written as Bimatoprost SRHow we know
- Topical Bimatoprost for Chemical BlepharoplastyCompletedEarly Phase 1Tulane UniversityNCT02830776Written as bimatoprost 0.03% ophthalmic solutionHow we know
- Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the USCompletedPhase 4Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00847483Written as Bimatoprost .03% sterile ophthalmic solutionHow we know
- Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy ParticipantsWithdrawnNot applicableJonsson Comprehensive Cancer CenterNCT00999557Written as bimatoprost ophthalmic solutionHow we know
- Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular HypertensionCompletedPhase 3AllerganNCT02247804Written as Bimatoprost SRHow we know
- Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular HypertensionCompletedPhase 1/2AllerganNCT01157364Written as bimatoprost 20 µg generation 2How we know
- Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye PressureCompletedNot applicableNorthwestern UniversityNCT02448043Written as Bimatoprost 0.01%How we know
See all 87 studies that test Bimatoprost →
Given beside what is tested · 3 — Bimatoprost is usual care or a partner of the new treatment
- Dose-Ranging Study of the Bimatoprost Ocular InsertCompletedPhase 2ForSight Vision5, Inc.NCT02358369Written as BimatoprostHow we know
- Safety and Efficacy of a Drug Delivery System in GlaucomaCompletedPhase 2Vistakon PharmaceuticalsNCT01016691Written as bimatoprost 0.03%How we know
- A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular HypertensionCompletedPhase 4AllerganNCT01525173Written as 0.01% bimatoprost ophthalmic solutionHow we know
As the comparator · 10 — what is tested is compared with Bimatoprost
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.RecruitingPhase 3Amneal Pharmaceuticals, LLCNCT05401357Written as Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)How we know
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle GlaucomaCompletedPhase 3Mankind Pharma LimitedNCT04890106Written as Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)How we know
- A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular HypertensionWithdrawnPhase 3Sun Pharmaceutical Industries LimitedNCT03927443Written as LumiganHow we know
- Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit DoseCompletedPhase 4Laboratoires TheaNCT02017327Written as Lumigan 0.01%How we know
- An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®CompletedPhase 4Alcon ResearchNCT01664039Written as Bimatoprost 0.01% ophthalmic solutionHow we know
- Bimatoprost in the Treatment of Eyelash HypotrichosisCompletedPhase 3AllerganNCT01698554Written as bimatoprost solution 0.03 %How we know
- A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular HypertensionCompletedPhase 2AllerganNCT01863953Written as Bimatoprost Ophthalmic Solution 0.01%How we know
- Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedPhase 2AllerganNCT01110499Written as bimatoprost ophthalmic solution 0.03%How we know
- Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle GlaucomaCompletedPhase 1/2AllerganNCT00809848Written as bimatoprost ophthalmic solution 0.03%How we know
- Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic SolutionCompletedPhase 2AllerganNCT01001195Written as bimatoprost ophthalmic solution 0.03%How we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
Codes
What other systems call Bimatoprost · ClinicalTrials.gg INT006613
- MeSH (NLM) D000069580BimatoprostConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) QXS94885MZBIMATOPROSTConfirmed FDA, NLM, Wikidata
- RxNorm 283810Confirmed FDA, Wikidata
- Wikidata Q2393348bimatoprostConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47414BimatoprostOne source FDA
- DrugBank DB00905One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069580 | Bimatoprost | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | QXS94885MZ | BIMATOPROST | Confirmed FDA, NLM, Wikidata |
| RxNorm | 283810 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2393348 | bimatoprost | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47414 | Bimatoprost | One source FDA |
| DrugBank | DB00905 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.